Tango Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Tango Therapeutics Free Cash Flow (FCF) History (TNGX)
Tango Therapeutics reported −$139.9M in free cash flow for fiscal 2025, a decrease of $7.7M from the previous fiscal year, with a free cash flow margin of −224.31%.
View full Tango Therapeutics company overviewTango Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$139.9M | −$7.7M | — | −224.31% |
| 2024 | 2024-12-31 | −$132.3M | −$12.7M | — | −314.38% |
| 2023 | 2023-12-31 | −$119.5M | −$2.7M | — | −327.18% |
| 2022 | 2022-12-31 | −$116.8M | −$55.4M | — | −469.72% |
| 2021 | 2021-12-31 | −$61.4M | −$130.3M | — | −165.66% |
| 2020 | 2020-12-31 | $69.0M | — | — | +900.84% |
Tango Therapeutics quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$38.9M | −$1.7M | — | — |
| Q1 2026 | 2026-03-31 | −$44.4M | −$2.6M | — | — |
| Q4 2025 | 2025-12-31 | −$29.9M | $6.8M | — | — |
| Q3 2025 | 2025-09-30 | −$31.1M | $2.4M | — | −57.80% |
| Q2 2025 | 2025-06-30 | −$37.1M | −$13.2M | — | −1167.65% |
| Q1 2025 | 2025-03-31 | −$41.7M | −$3.7M | — | −774.26% |
| Q4 2024 | 2024-12-31 | −$36.8M | −$9.1M | — | −893.37% |
| Q3 2024 | 2024-09-30 | −$33.5M | −$2.4M | — | −288.66% |
| Q2 2024 | 2024-06-30 | −$23.9M | $1.2M | — | −120.39% |
| Q1 2024 | 2024-03-31 | −$38.1M | −$2.5M | — | −588.04% |
| Q4 2023 | 2023-12-31 | −$27.7M | $1.6M | — | −509.91% |
| Q3 2023 | 2023-09-30 | −$31.2M | −$8.3M | — | −290.26% |
| Q2 2023 | 2023-06-30 | −$25.1M | $8.2M | — | −172.19% |
| Q1 2023 | 2023-03-31 | −$35.5M | −$4.3M | — | −616.15% |
| Q4 2022 | 2022-12-31 | −$29.3M | −$11.7M | — | −457.14% |
| Q3 2022 | 2022-09-30 | −$22.9M | −$622,000 | — | −330.78% |
| Q2 2022 | 2022-06-30 | −$33.3M | −$25.6M | — | −577.87% |
| Q1 2022 | 2022-03-31 | −$31.2M | −$17.4M | — | −542.31% |
| Q4 2021 | 2021-12-31 | −$17.6M | — | — | −307.87% |
| Q3 2021 | 2021-09-30 | −$22.3M | — | — | −328.10% |
| Q2 2021 | 2021-06-30 | −$7.7M | — | — | −42.53% |
| Q1 2021 | 2021-03-31 | −$13.8M | — | — | −215.75% |
Tango Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $69.0M to −$139.9M, a net decrease of $208.9M. Tango Therapeutics's latest reported quarter, Q2 2026, generated −$38.9M in free cash flow, a decrease of $1.7M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Tango Therapeutics filings at SEC.gov ↗